비교리스트

 카트 문의
시장보고서
상품코드
1701659

PARP 억제제 바이오마커 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

PARP Inhibitor Biomarkers Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
발행일: | 리서치사: Persistence Market Research | 페이지 정보: 영문 180 Pages | 배송안내 : 2-5일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

주요 조사 결과

  • PARP 억제제 바이오마커 시장 규모 : 10억 3,530만 달러(2025년)
  • 예상 시장 규모 : 18억 3,340만 달러(2032년)
  • 세계 시장 성장률 : 8.5%(2025-2032년 CAGR)

PARP 억제제 바이오마커 시장 - 보고서 범위

PARP(폴리 ADP 리보스 중합효소) 억제제 바이오마커는 PARP 억제제 치료의 혜택을 받을 수 있는 환자를 식별하는 데 매우 중요하며, 특히 종양 분야에서 중요합니다. 이러한 바이오마커에는 BRCA1/2 돌연변이, 상동 재조합 복구 결손(HRD), 기타 DNA 손상 반응(DDR) 경로의 변화가 포함됩니다. 시장은 특히 난소암, 유방암, 전립선암, 췌장암 등의 치료에 있어 임상의를 지원함으로써 정밀 종양학 진료에 기여하고 있습니다. 맞춤형 의료에 대한 수요가 증가함에 따라 바이오마커 기반 치료 접근법의 채택이 가속화되고 있습니다. 유전체 프로파일링, 차세대 염기서열 분석(NGS), 동반진단의 발전이 시장 성장에 크게 기여하고 있습니다.

시장 성장 촉진요인

세계 PARP 억제제 바이오마커 시장은 암 발병률 증가와 표적치료에 대한 수요 증가에 힘입어 성장하고 있으며, PARP 억제제가 여러 암에 대한 치료제로 승인됨에 따라 바이오마커 상태를 기반으로 적격 환자를 식별하는 동반진단 검사에 대한 요구가 증가하고 있습니다. PARP 억제제에 대한 반응성 예측인자로 BRCA 유전자 변이 및 HRD에 대한 인식이 높아짐에 따라 바이오마커 검사의 수가 증가하고 있습니다. 또한, 유지요법 및 병용요법에서 PARP 억제제의 사용이 확대되면서 바이오마커 연구에 대한 투자가 증가하고 있습니다. 정밀 종양학에 대한 정부의 지원과 유전체 의료 인프라에 대한 투자 확대도 시장 성장을 견인하고 있습니다.

시장 억제요인

PARP 억제제 바이오마커 시장은 큰 성장 잠재력에도 불구하고 여러 가지 제약에 직면해 있습니다. 바이오마커 검사 및 차세대 염기서열 분석 기술과 관련된 높은 비용, 특히 중저소득 지역에서는 높은 비용으로 인해 어려움을 겪고 있습니다. 동반진단 약품에 대한 상환 장애물과 복잡한 규제는 새로운 검사의 시장 진입을 지연시킬 수 있습니다. 또한, PARP 억제제의 적격성을 검사하는 바이오마커 검사에 대한 임상의와 환자들의 인식이 제한적이어서 광범위한 채택을 저해하고 있습니다. 검사 기준의 편차 및 전문 검사 시설에 대한 접근성이 미개발 지역에서의 시장 확대를 더욱 제한하고 있습니다.

시장 기회

PARP 억제제의 적용 범위를 확대할 수 있는 BRCA 유전자 변이 이외의 신규 바이오마커 개발에는 큰 기회가 존재합니다. 동반진단을 공동 개발하는 제약기업과 진단기업 간의 제휴는 유망한 성장 수단이 될 수 있습니다. 유전체 데이터 해석에 AI와 머신러닝의 통합은 바이오마커 탐색과 임상적 의사결정을 강화할 것으로 예측됩니다. 또한, 원격의료와 재택 유전자 검사 플랫폼의 보급이 확대되면서 바이오마커 검사 및 환자 대상 아웃리치에 새로운 채널이 제공될 것으로 보입니다. 신흥시장 진출과 액체 생검 기술의 진화도 미개발된 성장 가능성을 보여주고 있습니다.

이 보고서는 세계 PARP 억제제 바이오마커 시장을 조사하여 성장 촉진요인, 동향, 기회, 과제 등 시장 역학에 대한 상세한 분석을 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

  • 시장 범위와 정의
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 기회
    • 주요 동향
  • 거시경제 요인
    • 세계의 부문 전망
    • 세계의 GDP 성장 전망
  • COVID-19의 영향 분석
  • 예측요인 - 관련성과 영향

제3장 부가가치 인사이트

  • 제품 채용 분석
  • 규제 상황
  • Porter's Five Forces 분석
  • PESTLE 분석
  • 프로모션 전략 : 주요 기업별

제4장 세계의 PARP 억제제 바이오마커 시장 전망

  • 주요 하이라이트
    • 시장 규모와 전년비 성장
    • 절대적 수익 기회
  • 시장 규모 분석과 예측
    • 시장 규모 실적 분석(2019-2024년)
    • 현재 시장 규모 분석과 예측(2025-2032년)
  • 세계의 PARP 억제제 바이오마커 시장 전망 : 제품
    • 소개/주요 조사 결과
    • 시장 규모 실적 분석 : 제품별(2019-2024년)
    • 현재 시장 규모 분석과 예측 : 제품별(2025-2032년)
    • 시장 매력 분석 : 제품
  • 세계의 PARP 억제제 바이오마커 시장 전망 : 용도
    • 소개/주요 조사 결과
    • 시장 규모 실적 : 용도별(2019-2024년)
    • 현재 시장 규모 분석과 예측 : 용도별(2025-2032년)
    • 시장 매력 분석 : 용도
  • 세계의 PARP 억제제 바이오마커 시장 전망 : 최종사용자
    • 소개/주요 조사 결과
    • 시장 규모 실적 : 최종사용자별(2019-2024년)
    • 현재 시장 규모 분석과 예측 : 최종사용자별(2025-2032년)
    • 시장 매력 분석 : 최종사용자

제5장 세계의 PARP 억제제 바이오마커 시장 전망 : 지역

  • 주요 하이라이트
  • 시장 규모 실적 분석 : 지역별(2019-2024년)
  • 현재 시장 규모 분석과 예측 : 지역별(2025-2032년)
    • 북미
    • 유럽
    • 동아시아
    • 남아시아 및 오세아니아
    • 라틴아메리카
    • 중동 및 아프리카
  • 시장 매력 분석 : 지역

제6장 북미의 PARP 억제제 바이오마커 시장 전망

제7장 유럽의 PARP 억제제 바이오마커 시장 전망

제8장 동아시아의 PARP 억제제 바이오마커 시장 전망

제9장 남아시아 및 오세아니아의 PARP 억제제 바이오마커 시장 전망

제10장 라틴아메리카의 PARP 억제제 바이오마커 시장 전망

제11장 중동 및 아프리카의 PARP 억제제 바이오마커 시장 전망

제12장 경쟁 구도

  • 시장 점유율 분석(2025년)
  • 시장 구조
    • 경쟁 강도 맵 : 시장별
    • 경쟁 대시보드
  • 기업 개요(상세 - 개요, 재무, 전략, 최근 발전)
    • Myriad Genetics, Inc.
    • Illumina, Inc.
    • Amoy Diagnostics Co., Ltd.
    • QIAGEN
    • Agilent Technologies, Inc.
    • Quest Diagnostics Incorporated
    • Foundation Medicine, Inc.
    • OncoDNA
    • 4baseCare
    • AstraZeneca
    • Laboratory Corporation of America(R) Holdings
    • Genekor | MEDICAL S.A
    • Cambridge Bioscience Limited
    • BPS Bioscience, Inc.
    • BMG Labtech
    • R&D Systems, Inc(BioTechne)
    • BellBrook Labs
    • Abyntek Biopharma S.L.
    • Epic Sciences
    • Reaction Biology

제13장 부록

ksm 25.04.22

Persistence Market Research has recently released a comprehensive report on the worldwide market for PARP inhibitor biomarkers. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global PARP inhibitor biomarkers market from 2025 to 2032.

Key Insights:

  • PARP Inhibitor Biomarkers Market Size (2025E): USD 1,035.3 Million
  • Projected Market Value (2032F): USD 1,833.4 Million
  • Global Market Growth Rate (CAGR 2025 to 2032): 8.5%

PARP Inhibitor Biomarkers Market - Report Scope:

PARP (Poly ADP-ribose polymerase) inhibitor biomarkers are crucial in identifying patients who are likely to benefit from PARP inhibitor therapies, particularly in oncology applications. These biomarkers include BRCA1/2 mutations, homologous recombination deficiency (HRD), and other DNA damage response (DDR) pathway alterations. The market caters to precision oncology practices by aiding clinicians in tailoring cancer therapies, particularly for ovarian, breast, prostate, and pancreatic cancers. As the demand for personalized medicine rises, the adoption of biomarker-driven treatment approaches is accelerating. Advancements in genomic profiling, next-generation sequencing (NGS), and companion diagnostics are significantly contributing to market growth.

Market Growth Drivers:

The global PARP inhibitor biomarkers market is driven by the rising prevalence of cancer and increasing demand for targeted therapies. As PARP inhibitors gain regulatory approval for treating multiple cancers, there is a growing need for companion diagnostic tests to identify eligible patients based on biomarker status. The increasing awareness of BRCA gene mutations and HRD as predictors of response to PARP inhibitors is boosting biomarker testing volumes. Furthermore, expanding applications of PARP inhibitors in maintenance therapy and combination treatment regimens have fueled investments in biomarker research. Government initiatives to promote precision oncology and growing investments in genomic medicine infrastructure are also propelling market growth.

Market Restraints:

Despite strong growth potential, the PARP inhibitor biomarkers market faces several limitations. High costs associated with biomarker testing and next-generation sequencing technologies pose challenges, especially in low- and middle-income regions. Reimbursement hurdles and regulatory complexities surrounding companion diagnostics can delay market entry for new tests. Additionally, limited awareness among clinicians and patients about biomarker testing for PARP inhibitor eligibility hinders broader adoption. Variability in testing standards and access to specialized laboratories further restrict market expansion in underdeveloped areas.

Market Opportunities:

Significant opportunities exist in the development of novel biomarkers beyond BRCA mutations, which can broaden the scope of PARP inhibitor applications. Collaborations between pharmaceutical companies and diagnostic firms to co-develop companion diagnostics present a promising growth avenue. The integration of artificial intelligence and machine learning in genomic data interpretation is expected to enhance biomarker discovery and clinical decision-making. Furthermore, the increasing penetration of telemedicine and at-home genetic testing platforms provides new channels for biomarker testing and patient outreach. Expansion into emerging markets and the evolution of liquid biopsy techniques also represent untapped potential for growth.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the PARP inhibitor biomarkers market globally?
  • Which biomarker types and cancer indications are driving the adoption of PARP inhibitor testing?
  • How are technological innovations influencing the competitive landscape of the PARP inhibitor biomarkers market?
  • Who are the key players contributing to the market, and what strategies are they using to strengthen their positions?
  • What are the emerging trends and future prospects in the global PARP inhibitor biomarkers market?

Competitive Intelligence and Business Strategy:

Leading players in the global PARP inhibitor biomarkers market, including Myriad Genetics, Foundation Medicine, Thermo Fisher Scientific, and Illumina, Inc., are investing heavily in innovation, strategic partnerships, and co-development of companion diagnostics. These companies are leveraging their expertise in genomic testing and bioinformatics to develop accurate and efficient biomarker assays. Collaborations with pharmaceutical companies like AstraZeneca, Merck, and GlaxoSmithKline aim to accelerate the development of companion diagnostics aligned with PARP inhibitors. Key strategies include expanding testing portfolios, enhancing NGS capabilities, and strengthening global distribution networks to capture market share in both established and emerging regions.

Key Companies Profiled:

  • Myriad Genetics, Inc.
  • Illumina, Inc.
  • Amoy Diagnostics Co., Ltd.
  • QIAGEN
  • Agilent Technologies, Inc.
  • Quest Diagnostics Incorporated
  • Foundation Medicine, Inc.
  • OncoDNA
  • 4baseCare
  • AstraZeneca
  • Laboratory Corporation of America(R) Holdings
  • Genekor | MEDICAL S.A
  • Cambridge Bioscience Limited
  • BPS Bioscience, Inc.
  • BMG Labtech
  • R&D Systems, Inc (BioTechne)
  • BellBrook Labs
  • Abyntek Biopharma S.L.
  • Epic Sciences
  • Reaction Biology

PARP Inhibitor Biomarkers Market Segmentation

By Product:

  • BRCA 1 & 2 Testing Kits
  • Homologous Recombination Deficiency (HRD) Testing Kits
  • Homologous Recombination Repair (HRR) Testing Kits
  • Others

By Application:

  • Ovarian Cancer
  • Breast Cancer
  • Others

By End User:

  • Hospitals
  • Pharmaceutical Companies
  • Diagnostic Laboratories
  • Academic and Research Institutions
  • Others

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global PARP Inhibitor Biomarkers Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Regulatory Landscape
  • 3.3. Porter's Five Forces Analysis
  • 3.4. PESTLE Analysis
  • 3.5. Promotional Strategies, By Key Players

4. Global PARP Inhibitor Biomarkers Market Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Mn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
  • 4.3. Global PARP Inhibitor Biomarkers Market Outlook: Product
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
    • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
      • 4.3.3.1. BRCA 1 & 2 Testing Kits
      • 4.3.3.2. Homologous Recombination Deficiency (HRD) Testing Kits
      • 4.3.3.3. Homologous Recombination Repair (HRR) Testing Kits
      • 4.3.3.4. Others
    • 4.3.4. Market Attractiveness Analysis: Product
  • 4.4. Global PARP Inhibitor Biomarkers Market Outlook: Application
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Mn), By Application, 2019-2024
    • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
      • 4.4.3.1. Ovarian Cancer
      • 4.4.3.2. Breast Cancer
      • 4.4.3.3. Others
    • 4.4.4. Market Attractiveness Analysis: Application
  • 4.5. Global PARP Inhibitor Biomarkers Market Outlook: End User
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Mn), By End User, 2019-2024
    • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
      • 4.5.3.1. Hospitals
      • 4.5.3.2. Pharmaceutical Companies
      • 4.5.3.3. Diagnostic Laboratories
      • 4.5.3.4. Academic and Research Institutions
      • 4.5.3.5. Others
    • 4.5.4. Market Attractiveness Analysis: End User

5. Global PARP Inhibitor Biomarkers Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America PARP Inhibitor Biomarkers Market Outlook

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product
    • 6.2.3. By Application
    • 6.2.4. By End User
  • 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 6.4.1. BRCA 1 & 2 Testing Kits
    • 6.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
    • 6.4.3. Homologous Recombination Repair (HRR) Testing Kits
    • 6.4.4. Others
  • 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 6.5.1. Ovarian Cancer
    • 6.5.2. Breast Cancer
    • 6.5.3. Others
  • 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 6.6.1. Hospitals
    • 6.6.2. Pharmaceutical Companies
    • 6.6.3. Diagnostic Laboratories
    • 6.6.4. Academic and Research Institutions
    • 6.6.5. Others
  • 6.7. Market Attractiveness Analysis

7. Europe PARP Inhibitor Biomarkers Market Outlook

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product
    • 7.2.3. By Application
    • 7.2.4. By End User
  • 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 7.4.1. BRCA 1 & 2 Testing Kits
    • 7.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
    • 7.4.3. Homologous Recombination Repair (HRR) Testing Kits
    • 7.4.4. Others
  • 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 7.5.1. Ovarian Cancer
    • 7.5.2. Breast Cancer
    • 7.5.3. Others
  • 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 7.6.1. Hospitals
    • 7.6.2. Pharmaceutical Companies
    • 7.6.3. Diagnostic Laboratories
    • 7.6.4. Academic and Research Institutions
    • 7.6.5. Others
  • 7.7. Market Attractiveness Analysis

8. East Asia PARP Inhibitor Biomarkers Market Outlook

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product
    • 8.2.3. By Application
    • 8.2.4. By End User
  • 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 8.4.1. BRCA 1 & 2 Testing Kits
    • 8.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
    • 8.4.3. Homologous Recombination Repair (HRR) Testing Kits
    • 8.4.4. Others
  • 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 8.5.1. Ovarian Cancer
    • 8.5.2. Breast Cancer
    • 8.5.3. Others
  • 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 8.6.1. Hospitals
    • 8.6.2. Pharmaceutical Companies
    • 8.6.3. Diagnostic Laboratories
    • 8.6.4. Academic and Research Institutions
    • 8.6.5. Others
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania PARP Inhibitor Biomarkers Market Outlook

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product
    • 9.2.3. By Application
    • 9.2.4. By End User
  • 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 9.4.1. BRCA 1 & 2 Testing Kits
    • 9.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
    • 9.4.3. Homologous Recombination Repair (HRR) Testing Kits
    • 9.4.4. Others
  • 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 9.5.1. Ovarian Cancer
    • 9.5.2. Breast Cancer
    • 9.5.3. Others
  • 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 9.6.1. Hospitals
    • 9.6.2. Pharmaceutical Companies
    • 9.6.3. Diagnostic Laboratories
    • 9.6.4. Academic and Research Institutions
    • 9.6.5. Others
  • 9.7. Market Attractiveness Analysis

10. Latin America PARP Inhibitor Biomarkers Market Outlook

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product
    • 10.2.3. By Application
    • 10.2.4. By End User
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 10.4.1. BRCA 1 & 2 Testing Kits
    • 10.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
    • 10.4.3. Homologous Recombination Repair (HRR) Testing Kits
    • 10.4.4. Others
  • 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 10.5.1. Ovarian Cancer
    • 10.5.2. Breast Cancer
    • 10.5.3. Others
  • 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 10.6.1. Hospitals
    • 10.6.2. Pharmaceutical Companies
    • 10.6.3. Diagnostic Laboratories
    • 10.6.4. Academic and Research Institutions
    • 10.6.5. Others
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa PARP Inhibitor Biomarkers Market Outlook

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product
    • 11.2.3. By Application
    • 11.2.4. By End User
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 11.4.1. BRCA 1 & 2 Testing Kits
    • 11.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
    • 11.4.3. Homologous Recombination Repair (HRR) Testing Kits
    • 11.4.4. Others
  • 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 11.5.1. Ovarian Cancer
    • 11.5.2. Breast Cancer
    • 11.5.3. Others
  • 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 11.6.1. Hospitals
    • 11.6.2. Pharmaceutical Companies
    • 11.6.3. Diagnostic Laboratories
    • 11.6.4. Academic and Research Institutions
    • 11.6.5. Others
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Myriad Genetics, Inc.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Illumina, Inc.
    • 12.3.3. Amoy Diagnostics Co., Ltd.
    • 12.3.4. QIAGEN
    • 12.3.5. Agilent Technologies, Inc.
    • 12.3.6. Quest Diagnostics Incorporated
    • 12.3.7. Foundation Medicine, Inc.
    • 12.3.8. OncoDNA
    • 12.3.9. 4baseCare
    • 12.3.10. AstraZeneca
    • 12.3.11. Laboratory Corporation of America(R) Holdings
    • 12.3.12. Genekor | MEDICAL S.A
    • 12.3.13. Cambridge Bioscience Limited
    • 12.3.14. BPS Bioscience, Inc.
    • 12.3.15. BMG Labtech
    • 12.3.16. R&D Systems, Inc (BioTechne)
    • 12.3.17. BellBrook Labs
    • 12.3.18. Abyntek Biopharma S.L.
    • 12.3.19. Epic Sciences
    • 12.3.20. Reaction Biology

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제